Loading data for SNGX — first visit, this takes a few seconds.
Soligenix, Inc. (SNGX)
NasdaqCM: SNGX
· Real-Time Price · USD
0.37
+0.01 (2.78%)
At close: Sep 04, 2026, 8:00 PM
0.38
+0.03%
After-hours: 6:56 PM
The price, the headline numbers and the latest news, in one place.
Soligenix, Inc. (SNGX) Stock Price, Analysis & Data
No data available
| Bid | 0.26 |
| Market Cap | 8.27M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.2M |
| 1.92 | |
| -0.72 | |
| n/a | |
| -1.52 | |
| P/B (ttm) | 1.24 |
| P/S (ttm) | 0.00 |
| Earnings Date | n/a |
| Ask | 0.47 |
| Volume | 139,546 |
| Avg. Volume (20D) | 381,212 |
| Open | 0.36 |
| Previous Close | 0.36 |
| Day's Range | 0.36 - 0.37 |
| 52-Week Range | 0.28 - 2.98 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About SNGX
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX94...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 4, 1994
Employees 13
Stock Exchange NasdaqCM
Ticker Symbol SNGX
Website https://www.soligenix.com
Financial Performance
In 2025, Soligenix's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -11.08M, an increase of 34.04%.
Financial StatementsEarnings Surprise
Soligenix has released their quarterly earnings on Invalid Date:
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of misses estimates by , with NaN% YoY growth.
